Rheumatology Advance Access originally published online on March 1, 2005
Rheumatology 2005 44(5):587-596; doi:10.1093/rheumatology/keh552
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Pathogenesis of Raynaud's phenomenon
University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD and University of Manchester ARC Epidemiology Unit, Manchester M13 9PT, UK.
Correspondence to: aherrick{at}fs1.ho.man.ac.uk
The pathogenesis of Raynaud's phenomenon is not fully understood. However, the last 20 yr have witnessed enormous increases in our understanding of different mechanisms which, singly or in combination, may contribute. A key point is that Raynaud's phenomenon can be either primary (idiopathic) or secondary to a number of underlying conditions, and that the pathogenesis and pathophysiology vary between these conditions. This review concentrates upon those subtypes of Raynaud's phenomenon of most interest to rheumatologists: systemic sclerosis-related Raynaud's phenomenon, primary Raynaud's phenomenon and Raynaud's phenomenon secondary to hand–arm vibration syndrome. In this review, I shall discuss the main mechanisms thought to be important in pathophysiology under the three broad headings of ‘vascular’, ‘neural’ and ‘intravascular’. While these are false distinctions because all interrelate, they facilitate discussion of the key elements: the blood vessel wall (particularly the endothelium), the neural control of vascular tone, and the many circulating factors which can impair blood flow and/or cause endothelial injury. Vascular abnormalities include those of both structure and function. Neural abnormalities include deficiency of the vasodilator calcitonin gene-related peptide (released from sensory afferents), 
2-adrenoreceptor activation (possibly with up-regulation of the normally ‘silent’ 2C-adrenoreceptor) and a central nervous system component. Intravascular abnormalities include platelet activation, impaired fibrinolysis, increased viscosity and probably oxidant stress. As our understanding of the pathophysiology of Raynaud's phenomenon increases, so do our possibilities for identifying effective treatments.
KEY WORDS: Raynaud's phenomenon, Pathophysiology, Endothelium, Nervous system, Platelet aggregation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. ROSATO, F. BORGHESE, S. PISARRI, and F. SALSANO Laser Doppler Perfusion Imaging Is Useful in the Study of Raynaud's Phenomenon and Improves the Capillaroscopic Diagnosis J Rheumatol, October 1, 2009; 36(10): 2257 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. SCHIOPU, V. M. HSU, A. J. IMPENS, J. A. ROTHMAN, D. A. McCLOSKEY, J. E. WILSON, K. PHILLIPS, and J. R. SEIBOLD Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis J Rheumatol, October 1, 2009; 36(10): 2264 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Roberts and S. Tomlinson Cerebral vasospasm and primary Raynaud's phenomenon Br. J. Anaesth., November 1, 2008; 101(5): 743 - 744. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dooley, S. Y. Low, A. Holmes, A. G. Kidane, D. J. Abraham, C. M. Black, and K. R. Bruckdorfer Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis Rheumatology, March 1, 2008; 47(3): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chikura, T. L. Moore, J. B. Manning, A. Vail, and A. L. Herrick Sparing of the thumb in Raynaud's phenomenon Rheumatology, February 1, 2008; 47(2): 219 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. A. Fontenelle, C. Kayser, M. L. C. Pucinelli, and L. E. C. Andrade Cold stimulus fingertip lacticemy test an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis Rheumatology, January 1, 2008; 47(1): 80 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Buell, E. Tobinick, and K. Lamp Resolution of Chronic Pain and Fingertip Ulceration Due to Hand-Arm Vibration Syndrome Following Combination Pharmacotherapy Arch Dermatol, October 1, 2007; 143(10): 1343 - 1344. [Full Text] [PDF]
|
|
|
|
 |
|
 E. P K Yu, A. J K Ostor, and F. C Hall Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis Ann Rheum Dis, August 1, 2007; 66(8): 1122 - 1123. [Full Text] [PDF]
|
|
|
|
|
|
C. Sunderkotter and G. Riemekasten Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis Rheumatology, October 1, 2006; 45(suppl_3): iii33 - iii35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Selenko-Gebauer, N. Duschek, G. Minimair, G. Stingl, and F. Karlhofer Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan Rheumatology, October 1, 2006; 45(suppl_3): iii45 - iii48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dooley, B. Gao, N. Bradley, D. J. Abraham, C. M. Black, M. Jacobs, and K. R. Bruckdorfer Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine Rheumatology, June 1, 2006; 45(6): 676 - 684. [Abstract] [Full Text] [PDF]
|
|